This study aimed to compare and analyse the genomic features in cerebrospinal fluid (CSF) between patients with both brain parenchymal metastasis (BM) and meningeal metastasis (MM) of lung cancer and patients with MM only. 34 patients with lung adenocarcinoma were included in this study, including 18 patients in the BM in the MM group, there was a strong co-exclusion of EGFR and KRAS mutations. Chromosomal copy number variation analysis showed significant amplification in the MM group at the p15.33 bands on chromosome 5 and the 7p11.2 bands on chromosome 7. In the comparative analysis of tumour markers and CSF biochemical parameters between the two groups, no significant differences were found. This study revealed significant differences in CSF genomic characteristics between patients with simultaneous BM and MM of lung cancer and patients with MM only. These differences provide potential biomarkers for the precise treatment of patients with brain metastases and help to distinguish patients with lung cancer brain metastases with different metastatic patterns.
Sun et al. (Tue,) studied this question.